New Stock News | Jiangnan Mining Plans to List on Hong Kong IPO and is Currently Selecting Mining Consultants.
On May 24, 2026, Jiangnan Mining announced that the Board of Directors had approved the proposal to carry out preliminary preparations for a Hong Kong Stock Exchange IPO. The management was authorized to begin the preliminary preparations and to make subsequent decisions based on the progress.
According to public information, Tibet Jiangnan Mining Co., Ltd. (referred to as Jiangnan Mining (873020.NQ)), is currently in the process of appointing a mining consultant for a Hong Kong IPO (qualified individuals). According to the announcement of the intermediary agency for the selection of the Hong Kong IPO mining consultant (qualified individuals) project (second time), the time to obtain the negotiation documents is from 9:00 on July 18, 2026 to 17:00 on July 27, 2026, and the deadline for submitting response documents is 14:00 on July 28, 2026. On May 24, 2026, Jiangnan Mining announced that the board of directors had approved the "Proposal on Carrying out Preparatory Work for Hong Kong IPO" and authorized the management to carry out preparatory work and follow-up decision-making procedures according to the progress.
The information shows that the main business of Tibet Jiangnan Mining Co., Ltd. is the exploration, development, and sales of mineral resources mainly of ferrochrome. The company's main products are chrome ore and real estate leasing.
Related Articles

Zhejiang Jianfeng Group's subsidiary, which produces injectable special citicoline, has obtained a drug registration certificate.

New Stock Outlook | With a 10-fold increase in revenue and over 900 million dollars in losses over the past three years, when will Zhendrive Technology's economies of scale lead to a turning point in profitability?

Zhejiang Conba Pharmaceutical (600572.SH) subsidiary's musk tongxin pill new indication clinical trial application approved.
Zhejiang Jianfeng Group's subsidiary, which produces injectable special citicoline, has obtained a drug registration certificate.

New Stock Outlook | With a 10-fold increase in revenue and over 900 million dollars in losses over the past three years, when will Zhendrive Technology's economies of scale lead to a turning point in profitability?

Zhejiang Conba Pharmaceutical (600572.SH) subsidiary's musk tongxin pill new indication clinical trial application approved.

RECOMMEND





